Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Wyszukujesz frazę ""Margolis DA"" wg kryterium: Autor


Wyświetlanie 1-19 z 19
Tytuł:
Factors affecting neutrophil and platelet reconstitution following T cell-depleted bone marrow transplantation: differential effects of growth factor type and role of CD34 cell dose
Autorzy:
Keever-Taylor, CA
Klein, JP
Eastwood, D
Bredeson, C
Margolis, DA
Burns, WH
Vesole, DH
Pokaż więcej
Źródło:
Bone Marrow Transplantation: Official journal of the European Society for Blood and Marrow Transplantation. 27(8):791-800
Czasopismo naukowe
Tytuł:
The ASSURE study: HIV-1 suppression is maintained with bone and renal biomarker improvement 48 weeks after ritonavir discontinuation and randomized switch to abacavir/lamivudine + atazanavir.
Autorzy:
Wohl, DA
Bhatti, L
Small, CB
Edelstein, H
Zhao, HH
Margolis, DA
DeJesus, E
Weinberg, WG
Ross, LL
Shaefer, MS
Pokaż więcej
Temat:
BIOMARKERS
HIV
HIV infections
HIV-positive persons
STATISTICAL sampling
LAMIVUDINE
DATA analysis software
ABACAVIR
ABACAVIR-lamivudine (Drug)
ATAZANAVIR
DESCRIPTIVE statistics
Źródło:
HIV Medicine; Feb2016, Vol. 17 Issue 2, p106-117, 12p
Czasopismo naukowe
Tytuł:
Improving CT prediction of treatment response in patients with metastatic colorectal carcinoma using statistical learning theory
Autorzy:
Krupinski Elizabeth A
Gottlieb Ronald
Margolis Dan
Land Walker H
Yang Jack Y
Pokaż więcej
Temat:
Biotechnology
TP248.13-248.65
Genetics
QH426-470
Źródło:
BMC Genomics, Vol 11, Iss Suppl 3, p S15 (2010)
Opis pliku:
electronic resource
Relacje:
https://doaj.org/toc/1471-2164
Dostęp URL:
https://doaj.org/article/fe303309d156416783a5f7f96c109e59  Link otwiera się w nowym oknie
Czasopismo naukowe
Tytuł:
The role of reactive oxygen intermediates in experimental coccidioidomycois in mice
Autorzy:
Viriyakosol Suganya
Margolis David A
Fierer Joshua
Kirkland Theo N
Pokaż więcej
Temat:
Coccidioidomycosis
host response
oxidative burst
Microbiology
QR1-502
Źródło:
BMC Microbiology, Vol 11, Iss 1, p 71 (2011)
Opis pliku:
electronic resource
Relacje:
http://www.biomedcentral.com/1471-2180/11/71; https://doaj.org/toc/1471-2180
Dostęp URL:
https://doaj.org/article/6e28e2b0fbb64374a3c17a4cfc98e978  Link otwiera się w nowym oknie
Czasopismo naukowe
Tytuł:
A placebo-controlled pilot study of intensification of antiretroviral therapy with mycophenolate mofetil
Autorzy:
Turner Diana
Kvanli Mary
Bedimo Roger
Kaur Rupinderjeet
Shaw Leslie
Margolis David
Pokaż więcej
Temat:
Immunologic diseases. Allergy
RC581-607
Źródło:
AIDS Research and Therapy, Vol 3, Iss 1, p 16 (2006)
Opis pliku:
electronic resource
Relacje:
http://www.aidsrestherapy.com/content/3/1/16; https://doaj.org/toc/1742-6405
Dostęp URL:
https://doaj.org/article/b2baafab33b44f099b405bbb35944509  Link otwiera się w nowym oknie
Czasopismo naukowe
Tytuł:
Efficacy, Safety, and Durability of Long-Acting Cabotegravir and Rilpivirine in Adults With Human Immunodeficiency Virus Type 1 Infection: 5-Year Results From the LATTE-2 Study.
Autorzy:
Smith GHR; Maple Leaf Research, Toronto, Ontario, Canada.
Henry WK; Department of Medicine, Hennepin County Medical Center, Minneapolis, Minnesota, USA.
Podzamczer D; HIV Unit, Department of Infectious Diseases, Hospital Universitari de Bellvitge, L'Hospitalet, Barcelona, Spain.
Masiá MDM; Infectious Diseases Unit, Hospital General Universitario de Elche, Elche, Spain.
Bettacchi CJ; North Texas Infectious Disease Consultants, Dallas, Texas, USA.
Arasteh K; Epimed GmbH, Berlin, Germany.
Jaeger H; MVZ Karlsplatz, HIV Research and Clinical Care Centre, Munich, Germany.
Khuong-Josses MA; Service Maladies Infectieuses, CHG-Hôpital Delafontaine, Saint Denis, France.
Montes-Ramírez ML; HIV Unit, Service of Internal Medicine, Hospital La Paz Institute for Health Research, Madrid, Spain.
Stellbrink HJ; ICH Study Center, Hamburg, Germany.
Yazdanpanah Y; Infectious Disease Department, Hôpital Bichat Claude Bernard, Paris, France.
Richmond GJ; Gary J. Richmond, Fort Lauderdale, Florida, USA.
Sutton KC; Clinical Development, ViiV Healthcare, Research Triangle Park, North Carolina, USA.
Zhang F; Dev Biostatistics, GlaxoSmithKline, Collegeville, Pennsylvania, USA.
McCoig CC; Clinical Development, ViiV Healthcare, Tres Cantos, Spain.
St Clair MH; Department of Translational Medical Research, ViiV Healthcare, Research Triangle Park, North Carolina, USA.
Vandermeulen K; Medical Department of Infectious Diseases Therapeutic Area, Janssen Research and Development, Beerse, Belgium.
Van Solingen-Ristea R; Medical Department of Infectious Diseases Therapeutic Area, Janssen Research and Development, Beerse, Belgium.
Smith KY; Global Research and Medical Strategy, ViiV Healthcare, Research Triangle Park, North Carolina, USA.
Margolis DA; Clinical Development, ViiV Healthcare, Research Triangle Park, North Carolina, USA.
Spreen WR; Medicines Development, ViiV Healthcare, Research Triangle Park, North Carolina, USA.
Pokaż więcej
Źródło:
Open forum infectious diseases [Open Forum Infect Dis] 2021 Aug 25; Vol. 8 (9), pp. ofab439. Date of Electronic Publication: 2021 Aug 25 (Print Publication: 2021).
Typ publikacji:
Journal Article
Czasopismo naukowe
Tytuł:
HLA-B*57:01 allele prevalence in HIV-infected North American subjects and the impact of allele testing on the incidence of abacavir-associated hypersensitivity reaction in HLA-B*57:01-negative subjects.
Autorzy:
Small CB; Weill Cornell Medical College, New York, NY, USA.; New York Medical College, Valhalla, NY, USA.
Margolis DA; ViiV Healthcare, Research Triangle Park, NC, USA.
Shaefer MS; ViiV Healthcare, Research Triangle Park, NC, USA.
Ross LL; ViiV Healthcare, Research Triangle Park, NC, USA. .
Pokaż więcej
Źródło:
BMC infectious diseases [BMC Infect Dis] 2017 Apr 11; Vol. 17 (1), pp. 256. Date of Electronic Publication: 2017 Apr 11.
Typ publikacji:
Journal Article
MeSH Terms:
Anti-HIV Agents/*adverse effects
Dideoxynucleosides/*adverse effects
Drug Hypersensitivity/*immunology
HIV Infections/*immunology
HLA-B Antigens/*genetics
Adult ; Black or African American/genetics ; Anti-HIV Agents/therapeutic use ; CD4 Lymphocyte Count ; Dideoxynucleosides/therapeutic use ; Drug Hypersensitivity/genetics ; Female ; Gene Frequency ; HIV Infections/drug therapy ; HIV Infections/genetics ; HLA-B Antigens/immunology ; Humans ; Male ; Middle Aged ; United States ; White People/genetics
Czasopismo naukowe
Tytuł:
Disposition and metabolism of cabotegravir: a comparison of biotransformation and excretion between different species and routes of administration in humans.
Autorzy:
Bowers GD; a Department of Drug Metabolism and Pharmacokinetics , GlaxoSmithKline, Research Triangle Park , NC , USA .
Culp A; a Department of Drug Metabolism and Pharmacokinetics , GlaxoSmithKline, Research Triangle Park , NC , USA .
Reese MJ; a Department of Drug Metabolism and Pharmacokinetics , GlaxoSmithKline, Research Triangle Park , NC , USA .
Tabolt G; a Department of Drug Metabolism and Pharmacokinetics , GlaxoSmithKline, Research Triangle Park , NC , USA .
Moss L; a Department of Drug Metabolism and Pharmacokinetics , GlaxoSmithKline, Research Triangle Park , NC , USA .
Piscitelli S; b Infectious Diseases Medicines Discovery and Development, GlaxoSmithKline, Research Triangle Park , NC , USA .
Huynh P; a Department of Drug Metabolism and Pharmacokinetics , GlaxoSmithKline, Research Triangle Park , NC , USA .
Wagner D; a Department of Drug Metabolism and Pharmacokinetics , GlaxoSmithKline, Research Triangle Park , NC , USA .
Ford SL; c Project Clinical Platforms & Sciences, GlaxoSmithKline, Research Triangle Park , NC , USA , and.
Gould EP; c Project Clinical Platforms & Sciences, GlaxoSmithKline, Research Triangle Park , NC , USA , and.
Pan R; d Product Development, GlaxoSmithKline, Upper Providence , PA , USA.
Lou Y; c Project Clinical Platforms & Sciences, GlaxoSmithKline, Research Triangle Park , NC , USA , and.
Margolis DA; b Infectious Diseases Medicines Discovery and Development, GlaxoSmithKline, Research Triangle Park , NC , USA .
Spreen WR; b Infectious Diseases Medicines Discovery and Development, GlaxoSmithKline, Research Triangle Park , NC , USA .
Pokaż więcej
Źródło:
Xenobiotica; the fate of foreign compounds in biological systems [Xenobiotica] 2016; Vol. 46 (2), pp. 147-62. Date of Electronic Publication: 2015 Jul 01.
Typ publikacji:
Clinical Trial, Phase I; Comparative Study; Journal Article; Randomized Controlled Trial
MeSH Terms:
HIV Integrase Inhibitors/*pharmacokinetics
Pyridones/*pharmacokinetics
Administration, Oral ; Adult ; Animals ; Bile/metabolism ; Biotransformation ; Dose-Response Relationship, Drug ; Glucuronic Acid/urine ; Glucuronosyltransferase/metabolism ; HIV Integrase Inhibitors/administration & dosage ; HIV Integrase Inhibitors/blood ; Haplorhini ; Humans ; Male ; Mice ; Microsomes, Liver/metabolism ; Middle Aged ; Pyridones/administration & dosage ; Rats ; UDP-Glucuronosyltransferase 1A9
Czasopismo naukowe
Tytuł:
Simplification to abacavir/lamivudine + atazanavir maintains viral suppression and improves bone and renal biomarkers in ASSURE, a randomized, open label, non-inferiority trial.
Autorzy:
Wohl DA; AIDS Clinical Trials Unit, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States of America.
Bhatti L; AIDS Healthcare Foundation, Beverly Hills, California, United States of America.
Small CB; New York Medical College, Valhalla, New York, United States of America.
Edelstein H; Alameda County Medical Center, Oakland, California, United States of America.
Zhao HH; GlaxoSmithKline, Research Triangle Park, North Carolina, United States of America.
Margolis DA; GlaxoSmithKline, Research Triangle Park, North Carolina, United States of America.
DeJesus E; Orlando Immunology Center, Orlando, Florida, United States of America.
Weinberg WG; Kaiser Foundation Health Plan of Georgia, Inc, Atlanta, Georgia, United States of America.
Ross LL; ViiV Healthcare, Research Triangle Park, North Carolina, United States of America.
Shaefer MS; ViiV Healthcare, Research Triangle Park, North Carolina, United States of America.
Pokaż więcej
Źródło:
PloS one [PLoS One] 2014 May 13; Vol. 9 (5), pp. e96187. Date of Electronic Publication: 2014 May 13 (Print Publication: 2014).
Typ publikacji:
Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
MeSH Terms:
Anti-HIV Agents/*therapeutic use
Dideoxynucleosides/*therapeutic use
HIV Infections/*drug therapy
Lamivudine/*therapeutic use
Oligopeptides/*therapeutic use
Pyridines/*therapeutic use
Viral Load/*drug effects
Adult ; Aged ; Anti-HIV Agents/adverse effects ; Anti-HIV Agents/pharmacology ; Antiretroviral Therapy, Highly Active/adverse effects ; Atazanavir Sulfate ; Biomarkers/blood ; Dideoxynucleosides/adverse effects ; Dideoxynucleosides/pharmacology ; Drug Combinations ; Female ; HIV Infections/blood ; Humans ; Lamivudine/adverse effects ; Lamivudine/pharmacology ; Lipids/blood ; Male ; Middle Aged ; Oligopeptides/adverse effects ; Oligopeptides/pharmacology ; Pyridines/adverse effects ; Pyridines/pharmacology ; Treatment Outcome ; Young Adult
Czasopismo naukowe
Tytuł:
The role of reactive oxygen intermediates in experimental coccidioidomycois in mice.
Autorzy:
Margolis DA; Veterans Affairs San Diego Healthcare System (111F) 3350 La Jolla Village Dr, San Diego, CA 92161, USA.
Viriyakosol S
Fierer J
Kirkland TN
Pokaż więcej
Źródło:
BMC microbiology [BMC Microbiol] 2011 Apr 11; Vol. 11, pp. 71. Date of Electronic Publication: 2011 Apr 11.
Typ publikacji:
Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
MeSH Terms:
Coccidioides/*immunology
Coccidioidomycosis/*immunology
Reactive Oxygen Species/*immunology
Reactive Oxygen Species/*metabolism
Animals ; Coccidioidomycosis/mortality ; Coccidioidomycosis/pathology ; Colony Count, Microbial ; Disease Models, Animal ; Female ; Histocytochemistry ; Lung/microbiology ; Lung/pathology ; Male ; Membrane Glycoproteins/deficiency ; Mice ; Mice, Inbred C57BL ; Mice, Knockout ; Microscopy ; NADPH Oxidase 2 ; NADPH Oxidases/deficiency ; Survival Analysis
Czasopismo naukowe
Tytuł:
Stimulation by means of dendritic cells followed by Epstein-Barr virus-transformed B cells as antigen-presenting cells is more efficient than dendritic cells alone in inducing Aspergillus f16-specific cytotoxic T cell responses.
Autorzy:
Zhu F; Department of Medicine, Medical College of Wisconsin, Milwaukee, WI 53226, USA.
Ramadan G
Davies B
Margolis DA
Keever-Taylor CA
Pokaż więcej
Źródło:
Clinical and experimental immunology [Clin Exp Immunol] 2008 Feb; Vol. 151 (2), pp. 284-96. Date of Electronic Publication: 2007 Nov 14.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Allergens/*immunology
Antigen Presentation/*immunology
B-Lymphocytes/*immunology
Dendritic Cells/*immunology
T-Lymphocytes, Cytotoxic/*immunology
Antigen-Presenting Cells/immunology ; Antigens, Fungal/immunology ; Antigens, Plant ; Aspergillus/growth & development ; Aspergillus/immunology ; Cell Line ; Cell Transformation, Viral ; Cells, Cultured ; Cytotoxicity, Immunologic ; Epitopes, T-Lymphocyte/immunology ; Fungal Proteins ; Herpesvirus 4, Human ; Humans ; Hyphae/growth & development ; Hyphae/immunology ; Immunophenotyping ; Interferon-gamma/biosynthesis ; Interleukin-10/immunology ; Tumor Necrosis Factor-alpha/immunology
Czasopismo naukowe
    Wyświetlanie 1-19 z 19

    Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies